Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 15 NOVEMBER 2007

Insider Trading Is Back

Fenwick
Explore more from Fenwick

Remember Ivan Boesky, Dennis Levine, and Michael Milken? Many Wall Street professionals and corporate executives are too young to remember the insider trading scandals of the 1980s. And that is the problem. Insider trading cases against Wall Street professionals and corporate executives are back in a big way.

United StatesCorporate/Commercial Law
Christopher Steskal
Christopher Steskal
Author LinkedIn connections

Remember Ivan Boesky, Dennis Levine, and Michael Milken? Many Wall Street professionals and corporate executives are too young to remember the insider trading scandals of the 1980s. And that is the problem. Insider trading cases against Wall Street professionals and corporate executives are back in a big way.

Following the high profile insider trading cases in the 1980s, there were no SEC enforcement actions against Wall Street professionals between 1990 and 1995, and there were only cases against ten such individuals between 1995 and 2000. Now, in the first half of 2007, the SEC has sued over 20 professionals for insider trading.

Most of the SEC enforcement actions brought this year against Wall Street professionals and corporate executives involve insider trading in advance of mergers and acquisitions. And to be sure, the up tick in mergers and acquisitions activity in the past year has provided fertile ground for SEC enforcement actions. The following are examples:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP